The Claim
In adults with type 2 diabetes, once-daily liraglutide at doses of 0.6, 1.2, and 1.8 mg significantly reduces fasting plasma glucose by 15-25% compared to placebo, indicating a sustained effect on basal glucose regulation independent of meal-related stimuli.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, taking liraglutide once daily at doses of 0.6, 1.2, or 1.8 mg lowers fasting blood glucose levels by 15% to 25% compared to no treatment, showing a consistent effect on baseline glucose control unrelated to food intake.
See the scientific wording
In adults with type 2 diabetes, once-daily liraglutide at doses of 0.6, 1.2, and 1.8 mg significantly reduces fasting plasma glucose by 15-25% compared to placebo, indicating a sustained effect on basal glucose regulation independent of meal-related stimuli.
Liraglutide binds to receptors on the pancreas, causing beta cells to release more insulin when blood sugar is high. It also slows down how fast the stomach empties, so sugar from food enters the bloodstream more slowly. Together, these actions lower blood sugar even when a person hasn't eaten.
What the research says
1 studyIn people with type 2 diabetes, a daily shot of liraglutide lowered their fasting blood sugar by 15–25% compared to a placebo, meaning it helps control blood sugar even when they haven’t eaten.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.